Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Buy dildos and adult toys.
Popular Articles

NeurogesX Announces New PDUFA Date For Qutenza(TM) New Drug Application
NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced that the United States Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date from August 16, 2009 to November 16, 2009 to review the new drug application (NDA) for Qutenza(TM) to manage pain associated with postherpetic neuralgia (PHN).
buy viagra
A 'Heart Healthy' Diet And Ongoing, Moderate Physical Activity May Protect Against Cognitive Decline
Eating a "heart healthy" diet and maintaining or increasing participation in moderate physical activity may help preserve our memory and thinking abilities as we age, according to new research reported today at the Alzheimer"s Association 2009 International Conference on Alzheimer"s Disease (ICAD 2009) in Vienna.
News of the day
Seeking Solutions To The Chronic Nursing Shortage In Canada And The US
The Arthur Labatt Family School of Nursing at The University of Western Ontario has announced a $2 million research chair to address issues surrounding the chronic shortage of registered nurses in Canada and the United States. Dr. Heather Laschinger, Ph.D., was named the first Arthur Labatt Family Nursing Research Chair in Human Re Optimization.
Public Health

Results And Additional Analyses From Efficacy And Safety Study Of Corthera's Relaxin In Acute Heart Failure To Be Presented At Heart Failure Congress

Results and additional analyses from the Phase II portion of a Phase II/III clinical trial of Corthera"s investigational drug relaxin for the treatment of acute heart failure will be presented at the Heart Failure Congress, the annual meeting of the Heart Failure Association of the European Society of Cardiology in Nice, France. Marco Metra, M.D., professor of cardiology at the University of Brescia, Italy, and co-principal investigator of the Pre-RELAX-AHF study, will present the main results from the multicenter, international Pre-RELAX-AHF study at 8:30 a.m. CET on Sunday, May 31, at the Judges" Choice oral abstracts session. Dr. Metra will also present additional analyses of the Pre-RELAX-AHF study during a late-breaking clinical trials session at 11:15 a.m. CET on Monday, June 1. Five posters from the Pre-RELAX-AHF study will also be presented from 8:30 a.m. to 12:30 p.m. CET on Monday, June 1. About Relaxin Relaxin is a naturally occurring peptide hormone that acts as a systemic and renal vasodilator. Elevated levels of relaxin modulate increases in renal and cardiac function that meet the increased hemodynamic demands of pregnancy. Consistent with this natural role of the hormone, pharmaceutically manufactured relaxin has been shown to have these effects in multiple human studies of men and non-pregnant women, including patients with heart failure. About Corthera Corthera Inc. is a private biopharmaceutical company committed to acquiring, developing and commercializing therapies for illnesses in the acute care setting. Corthera"s lead product candidate, relaxin, is currently being evaluated in clinical trials for acute heart failure. The company has worldwide rights to develop and commercialize relaxin. Corthera Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009